GO:0046037 GMP metabolic process: Nucleotide Biosynthesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046037 (GMP metabolic process) describes all chemical reactions and pathways involving guanosine monophosphate (GMP), a purine ribonucleotide essential for RNA, DNA, and protein synthesis.
• GMP metabolism intersects with cyclic di-GMP signaling, a second messenger that regulates bacterial biofilm formation, virulence, and NAD biosynthesis.
• Key enzymes include GMP synthase (guaA), IMP dehydrogenase (guaB), and various phosphohydrolases and kinases that interconvert GMP, GDP, and GTP.
• Dysregulation of GMP metabolism is linked to neurological disorders, cancer, and bacterial pathogenesis through cGAS-STING and metabolic reprogramming.
• CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect GMP metabolic gene function in human cells and bacteria.
• Understanding GMP metabolic process provides targets for antimicrobial, anticancer, and immunomodulatory therapies.
Description
Guanosine monophosphate (GMP) is a purine ribonucleotide that serves as a building block for RNA and DNA and as a precursor for GDP, GTP, and cyclic GMP (cGMP). The Gene Ontology term GO:0046037, GMP metabolic process, encompasses the chemical reactions and pathways involving GMP, including its biosynthesis, interconversion, and degradation. This process is fundamental to cellular energy homeostasis, signal transduction, and nucleic acid synthesis across all domains of life. In bacteria, GMP metabolism is tightly linked to the second messenger cyclic di-GMP (c-di-GMP), which controls biofilm formation, motility, and virulence. Recent studies have revealed that c-di-GMP also regulates bacterial NAD biosynthesis via the transcriptional repressor NadR, highlighting the broad metabolic impact of GMP-related pathways. In eukaryotes, GMP metabolism supports neurotransmission and immune signaling, and its dysregulation has been implicated in epilepsy and neuroinflammation through mtDNA leakage and cGAS-STING-driven serine metabolic reprogramming. Researchers studying GMP metabolic process aim to understand how cells balance nucleotide pools, respond to stress, and coordinate growth with metabolism. This article provides a comprehensive overview of the molecular mechanisms, key genes, disease associations, and experimental models used to investigate GO:0046037.
GMP metabolic process At A Glance
| GO ID | GO:0046037 |
|---|---|
| GO term | GMP metabolic process |
| Ontology | biological_process |
| Synonym | GMP metabolism |
| Major function | Biosynthesis, interconversion, and degradation of guanosine monophosphate and its derivatives |
| Key enzymes | GMP synthase (guaA), IMP dehydrogenase (guaB), GMP reductase, nucleoside diphosphate kinase, c-di-GMP phosphodiesterases |
| Related second messengers | cGMP, cyclic di-GMP |
| Cellular compartments | Cytoplasm, bacterial membrane-associated complexes |
| Disease relevance | Epilepsy, neuroinflammation, bacterial infections, cancer metabolism |
What Is GO:0046037?
GMP metabolic process (GO:0046037) is defined by the Gene Ontology as the chemical reactions and pathways involving GMP, guanosine monophosphate. This includes the biosynthesis of GMP from IMP, the phosphorylation of GMP to GDP and GTP, the dephosphorylation of guanine nucleotides back to GMP, and the utilization of GMP in RNA synthesis or as a precursor for cGMP and c-di-GMP. The term captures both anabolic and catabolic routes that maintain intracellular GMP homeostasis.
Why Is GMP metabolic process Important in Cell Biology?
GMP metabolic process is central to nucleotide homeostasis, nucleic acid synthesis, and cellular signaling. It provides the precursor for GDP and GTP, which are required for protein synthesis, signal transduction, and microtubule dynamics. In bacteria, GMP derivatives such as c-di-GMP control the transition between motile and sessile lifestyles, influencing biofilm formation and virulence. Dysregulation of GMP metabolism has been linked to neurological disorders, including epilepsy, where mtDNA leakage triggers cGAS-STING-driven neuroinflammation and serine metabolic reprogramming. Moreover, c-di-GMP regulates bacterial NAD biosynthesis, connecting nucleotide metabolism to redox balance and stress responses. Understanding GMP metabolic process is therefore essential for developing therapies against infections, cancer, and inflammatory diseases.
• Provides guanine nucleotides for RNA and DNA synthesis.
• Supplies GTP for protein synthesis, signal transduction, and cytoskeletal dynamics.
• Generates cGMP, a key second messenger in vision and cardiovascular function.
• Produces c-di-GMP, a bacterial second messenger controlling biofilm and virulence.
• Links to NAD biosynthesis via NadR regulation in bacteria.
• Implicated in epilepsy and neuroinflammation through cGAS-STING and serine metabolism.
• Target for antimicrobial drugs that disrupt c-di-GMP signaling.
• Potential target for anticancer therapies exploiting altered nucleotide metabolism.
• Essential for immune cell function and inflammatory responses.
• Model system for studying metabolic reprogramming in disease.
What Happens During GMP metabolic process?
De novo biosynthesis of GMP
In simple terms: Cells build GMP from scratch using a series of enzymatic steps starting from a sugar and amino acid precursors.
The de novo pathway begins with the formation of IMP (inosine monophosphate) from ribose-5-phosphate and ATP. IMP is then converted to XMP by IMP dehydrogenase (guaB), and XMP is aminated to GMP by GMP synthase (guaA) using glutamine as a nitrogen donor. This pathway is highly conserved and essential for purine nucleotide supply in both prokaryotes and eukaryotes.
Salvage and interconversion of GMP
In simple terms: Cells can recycle guanine bases or convert GMP to other guanine nucleotides like GDP and GTP.
GMP can be synthesized from guanine via hypoxanthine-guanine phosphoribosyltransferase (HGPRT) in the salvage pathway. GMP is also interconverted with GDP and GTP by nucleoside diphosphate kinase and guanylate kinase. These reactions maintain the cellular pools of guanine nucleotides required for RNA, DNA, and protein synthesis.
Cyclic di-GMP synthesis and degradation
In simple terms: Bacteria use GMP to make a signaling molecule called c-di-GMP, which tells them to stick together and form biofilms.
c-di-GMP is synthesized from two GTP molecules by diguanylate cyclases (DGCs) containing GGDEF domains and degraded by phosphodiesterases (PDEs) with EAL or HD-GYP domains. This second messenger regulates biofilm formation, motility, and virulence in many bacterial pathogens. The balance between synthesis and degradation determines the cellular level of c-di-GMP and the resulting phenotypic output.
GMP as a precursor for cGMP and signaling
In simple terms: In animal cells, GMP is converted to cGMP, a messenger that controls vision, blood flow, and nerve signaling.
Guanylate cyclases convert GTP to cGMP, which acts as a second messenger in processes such as smooth muscle relaxation, phototransduction, and neurotransmission. cGMP is degraded by phosphodiesterases to GMP, completing the cycle. This pathway is targeted by drugs like sildenafil for erectile dysfunction and pulmonary hypertension.
Regulation of GMP metabolism by NadR
In simple terms: In bacteria, a protein called NadR senses c-di-GMP and controls genes for making NAD, linking GMP metabolism to energy production.
Recent work shows that c-di-GMP binds to the transcriptional repressor NadR, preventing it from repressing NAD biosynthesis genes. This connects GMP metabolism to NAD homeostasis and cellular redox balance. The interplay between c-di-GMP and NadR highlights how GMP metabolic process integrates with broader metabolic networks.
Key Genes Involved in GO:0046037 GMP metabolic process
The following genes and proteins are central to GMP metabolic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| guaA | GMP synthase; converts XMP to GMP | Essential for de novo GMP synthesis; target for antimicrobials |
| guaB | IMP dehydrogenase; converts IMP to XMP | Rate-limiting step in GMP biosynthesis; linked to cell proliferation |
| gmk | Guanylate kinase; phosphorylates GMP to GDP | Maintains nucleotide balance; potential drug target |
| ndk | Nucleoside diphosphate kinase; interconverts GDP/GTP | Supports GTP supply for signaling and synthesis |
| hprt | Hypoxanthine-guanine phosphoribosyltransferase; salvage of guanine to GMP | Deficiency causes Lesch-Nyhan syndrome |
| dgc | Diguanylate cyclase; synthesizes c-di-GMP from GTP | Regulates biofilm formation and virulence |
| pde | Phosphodiesterase; degrades c-di-GMP | Controls c-di-GMP levels; biofilm dispersal |
| nadR | Transcriptional repressor; regulated by c-di-GMP | Links GMP metabolism to NAD biosynthesis |
| cGAS | Cyclic GMP-AMP synthase; senses mtDNA | Triggers neuroinflammation in epilepsy |
| STING | Stimulator of interferon genes; adaptor in cGAS pathway | Mediates neuroinflammatory responses |
| GMPR | GMP reductase; converts GMP to IMP | Balances guanine nucleotide pools |
| NT5C | 5'-nucleotidase; dephosphorylates GMP to guanosine | Regulates nucleotide catabolism |
| PNP | Purine nucleoside phosphorylase; converts guanosine to guanine | Deficiency causes immunodeficiency |
| ADA | Adenosine deaminase; purine metabolism | Deficiency causes SCID |
| IMPDH1 | Inosine monophosphate dehydrogenase 1 | Retinal degeneration and cancer |
| IMPDH2 | Inosine monophosphate dehydrogenase 2 | Cell proliferation and cancer |
| GMPS | GMP synthase (human) | Potential target in cancer and viral infections |
How Is GMP metabolic process Regulated?
GMP metabolic process is regulated at multiple levels. In bacteria, c-di-GMP levels are controlled by the opposing activities of diguanylate cyclases and phosphodiesterases, which respond to environmental signals. The transcriptional repressor NadR is modulated by c-di-GMP binding, linking GMP metabolism to NAD biosynthesis. In eukaryotes, GMP synthesis is regulated by feedback inhibition of IMP dehydrogenase by GMP and by transcriptional control of guaA and guaB in response to nucleotide availability. Additionally, cGMP levels are tightly regulated by guanylate cyclases and phosphodiesterases, which are targets of nitric oxide and natriuretic peptides. In the context of neuroinflammation, mtDNA leakage activates cGAS-STING signaling, which reprograms serine metabolism and may indirectly affect GMP pools.
GMP metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| cGAS/STING | Epilepsy and neuroinflammation | Knockout mice, neuronal cell lines |
| dgc/pde | Biofilm-associated infections | Bacterial knockout and overexpression strains |
| IMPDH1/2 | Cancer and retinal degeneration | CRISPR knockout in cancer cell lines |
| HPRT | Lesch-Nyhan syndrome | Patient-derived iPSCs and knock-in mice |
| NadR | NAD biosynthesis and stress response | Bacterial point mutations and knockout |
Epilepsy and neuroinflammation
mtDNA leakage from neurons promotes neuron-glia crosstalk that induces epilepsy through cGAS-STING-driven neuroinflammation and serine metabolic reprogramming. This pathway intersects with GMP metabolism because cGAS produces cyclic GMP-AMP (cGAMP), a cyclic dinucleotide related to c-di-GMP, and because altered nucleotide metabolism can affect neuronal excitability.
Bacterial infections and biofilm-associated diseases
c-di-GMP, a derivative of GMP metabolism, is a central regulator of biofilm formation and virulence in bacterial pathogens. High c-di-GMP levels promote sessile biofilm lifestyles that are resistant to antibiotics and immune clearance, making GMP metabolic enzymes attractive antimicrobial targets.
Cancer metabolism
Altered GMP metabolism supports rapid cancer cell proliferation by providing guanine nucleotides for DNA and RNA synthesis. IMPDH inhibitors such as mycophenolic acid are used as immunosuppressants and have anticancer potential. Targeting GMP biosynthetic enzymes is an active area of drug discovery.
Lesch-Nyhan syndrome and purine disorders
Deficiency of HGPRT, which salvages guanine to GMP, causes Lesch-Nyhan syndrome, characterized by hyperuricemia and neurological dysfunction. This highlights the importance of GMP salvage pathways in human health.
From GMP metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does guaA knockout reduce GMP levels and impair growth? | CRISPR knockout in bacterial or human cell lines |
| Does a point mutation in NadR alter c-di-GMP binding? | Point mutation knock-in in bacteria |
| Can overexpression of DGC increase biofilm formation? | Overexpression plasmid in bacteria |
| Does tagged GMP synthase localize to specific compartments? | Tagged knock-in with fluorescent protein |
| Does cGAS knockout reduce neuroinflammation in epilepsy? | Knockout mice and neuronal cultures |
| Can IMPDH inhibitors block cancer cell proliferation? | CRISPR knockout of IMPDH in cancer cells |
How to Study the GMP metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | GMP, GDP, GTP, c-di-GMP levels | Quantifying nucleotide pools in cells |
| CRISPR knockout screens | Gene essentiality for GMP metabolism | Identifying novel regulators |
| Fluorescent c-di-GMP reporters | Intracellular c-di-GMP concentration | Live imaging of biofilm formation |
| RNA-seq | Transcriptional changes in GMP metabolic genes | Response to stress or infection |
| Immunocytochemistry | cGMP localization in tissues | Neuronal signaling studies |
| Enzyme activity assays | GMP synthase or IMPDH activity | Drug screening and kinetic studies |
| Mouse epilepsy models | Neuroinflammation and seizure severity | Testing cGAS-STING inhibitors |
| Bacterial biofilm assays | Biofilm formation and dispersal | Evaluating c-di-GMP pathway mutants |
Metabolomics and nucleotide quantification
Liquid chromatography-mass spectrometry (LC-MS) can quantify GMP, GDP, GTP, and c-di-GMP levels in cells and tissues. This method is essential for assessing the impact of genetic perturbations on GMP metabolic process.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes required for GMP metabolism and c-di-GMP signaling. These screens link genotype to phenotype and reveal novel regulators.
Reporter assays for c-di-GMP
Fluorescent reporters and riboswitches can monitor c-di-GMP levels in live bacteria. These tools enable real-time analysis of GMP-derived second messenger dynamics.
Animal models of epilepsy and neuroinflammation
Mouse models with mtDNA leakage and cGAS-STING activation are used to study epilepsy and neuroinflammation. These models help evaluate therapeutic interventions targeting GMP-related pathways.
How CRISPR Can Be Used to Study GO:0046037 GMP metabolic process
Knockout
CRISPR knockout of GMP metabolic genes such as guaA, guaB, or dgc can abolish GMP synthesis or c-di-GMP production, leading to growth defects or altered biofilm phenotypes. These models are used to validate gene essentiality and to study downstream effects on nucleotide pools.
Point Mutation
Point mutations in catalytic residues of GMP synthase or in the c-di-GMP binding pocket of NadR can dissect specific enzymatic activities and regulatory interactions. CRISPR-mediated base editing enables precise introduction of such mutations in endogenous loci.
Knock-in
Knock-in of fluorescent tags or epitope tags into GMP metabolic genes allows real-time localization and interaction studies. Tagged knock-in models are valuable for imaging cGMP or c-di-GMP signaling in live cells.
Overexpression
CRISPR activation (CRISPRa) or plasmid-based overexpression of diguanylate cyclases or GMP synthases can elevate c-di-GMP or GMP levels, respectively, to study gain-of-function phenotypes. Overexpression models are useful for testing sufficiency in signaling pathways.
How EDITGENE Supports GMP metabolic process Research
Researchers studying GMP metabolic process-related genes often need to determine whether a candidate gene is causally involved in nucleotide homeostasis, biofilm formation, or neuroinflammation. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from knockout to precise point mutations and overexpression.
Contact EDITGENE today to design your custom CRISPR model for GMP metabolic process research.
Frequently Asked Questions About GMP metabolic process
What is GMP metabolic process?
GMP metabolic process (GO:0046037) is the set of chemical reactions and pathways involving guanosine monophosphate, including its biosynthesis, interconversion, and degradation.
What genes are involved in GMP metabolic process?
Key genes include guaA, guaB, gmk, ndk, hprt, dgc, pde, and nadR, among others.
How is GMP metabolic process regulated?
It is regulated by feedback inhibition, transcriptional control, and second messenger signaling such as c-di-GMP and cGMP.
What diseases are associated with GMP metabolic process?
Diseases include epilepsy, neuroinflammation, bacterial biofilm infections, cancer, and Lesch-Nyhan syndrome.
What is the role of c-di-GMP in GMP metabolism?
c-di-GMP is a second messenger synthesized from GTP that regulates biofilm formation, motility, and virulence in bacteria.
How can CRISPR be used to study GMP metabolic process?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of GMP metabolic genes in various organisms.
What methods are used to measure GMP levels?
LC-MS metabolomics, fluorescent reporters, and enzyme activity assays are commonly used.
Is GMP metabolism linked to NAD biosynthesis?
Yes, c-di-GMP regulates the transcriptional repressor NadR, which controls NAD biosynthesis genes in bacteria.
What is the connection between GMP metabolism and epilepsy?
mtDNA leakage activates cGAS-STING signaling and serine metabolic reprogramming, which may intersect with GMP metabolism in neuroinflammation.
How does GMP metabolism affect cancer?
Altered GMP metabolism supports cancer cell proliferation by providing nucleotides for DNA and RNA synthesis, making it a therapeutic target.
Conclusion
GMP metabolic process (GO:0046037) is a fundamental biological pathway that governs guanine nucleotide homeostasis and second messenger signaling. Its roles in bacterial biofilm formation, neuroinflammation, cancer metabolism, and genetic disorders make it a rich area for research. By leveraging CRISPR-based models and advanced analytical methods, scientists can uncover new therapeutic targets and deepen our understanding of this essential process.
References
- 1. Jiang J et al.. 2026. mtDNA leakage promotes neuron-glia crosstalk to induce epilepsy by cGAS-STING-driven neuroinflammation and serine metabolic reprogramming.. Proc Natl Acad Sci U S A 123(9):e2522313123 PMID: 41734071
- 2. Mao L et al.. 2025. c-di-GMP regulates bacterial NAD biosynthesis via targeting the transcriptional repressor NadR.. mBio 16(9):e0198225 PMID: 40823837
- 3. de Vente J et al.. 1997. cGMP-immunocytochemistry.. Methods Mol Biol 72:125-43 PMID: 9249741
- 4. Chou SH et al.. 2016. Diversity of Cyclic Di-GMP-Binding Proteins and Mechanisms.. J Bacteriol 198(1):32-46 PMID: 26055114
- 5. Römling U et al.. 2006. Cyclic di-GMP as a second messenger.. Curr Opin Microbiol 9(2):218-28 PMID: 16530465
- 6. Hall CL et al.. 2018. Cyclic-di-GMP regulation of virulence in bacterial pathogens.. Wiley Interdiscip Rev RNA 9(1) PMID: 28990312
- 8. Jonas K et al.. 2009. Regulation of c-di-GMP metabolism in biofilms.. Future Microbiol 4(3):341-58 PMID: 19327118
